NO20060313L - Saquinavirmesylat oral doseringsform - Google Patents
Saquinavirmesylat oral doseringsformInfo
- Publication number
- NO20060313L NO20060313L NO20060313A NO20060313A NO20060313L NO 20060313 L NO20060313 L NO 20060313L NO 20060313 A NO20060313 A NO 20060313A NO 20060313 A NO20060313 A NO 20060313A NO 20060313 L NO20060313 L NO 20060313L
- Authority
- NO
- Norway
- Prior art keywords
- mesylate
- sakinavir
- dosage form
- oral dosage
- saquinavir mesylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det er tilveiebrakt en oral, fast, farmasøytisk enhetsdoseform av sakinavirmesylat, som omfatter mikronisert sakinavirmesylat i en mengde fra 250 mg til 800 mg beregnet som fri base, og et farmasøytisk akseptabelt bindemiddel, desintegrasjonsmiddel og vannoppløselig bærer. Det er tilveiebrakt en fast enhetsdoseform av sakinavirmesylat som omfatter fra 60% til 80% mikronisert sakinavirmesylat basert på mesylatsaltet, 4% til 8% vannoppløselig bindemiddel, et desintegrasjonsmiddel og en bærer, hvor hver prosentandel er basert på kjernevekten.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48660003P | 2003-07-11 | 2003-07-11 | |
US56820404P | 2004-05-05 | 2004-05-05 | |
PCT/EP2004/007309 WO2005004836A2 (en) | 2003-07-11 | 2004-07-05 | Saquinavir mesylate oral dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060313L true NO20060313L (no) | 2006-02-09 |
Family
ID=34068244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060313A NO20060313L (no) | 2003-07-11 | 2006-01-20 | Saquinavirmesylat oral doseringsform |
Country Status (24)
Country | Link |
---|---|
US (2) | US20050009811A1 (no) |
EP (1) | EP1646369B1 (no) |
JP (2) | JP4608488B2 (no) |
KR (2) | KR100767271B1 (no) |
AU (1) | AU2004255436B2 (no) |
BR (1) | BRPI0412523A (no) |
CA (1) | CA2531486C (no) |
CO (1) | CO5640069A2 (no) |
CR (1) | CR8172A (no) |
EA (1) | EA015349B1 (no) |
EC (1) | ECSP066274A (no) |
HK (1) | HK1089959A1 (no) |
IL (1) | IL172890A (no) |
MA (1) | MA27904A1 (no) |
MX (1) | MXPA06000363A (no) |
MY (1) | MY140413A (no) |
NO (1) | NO20060313L (no) |
NZ (1) | NZ544585A (no) |
PA (1) | PA8606001A1 (no) |
PE (1) | PE20050247A1 (no) |
RS (1) | RS20060009A (no) |
TN (1) | TNSN06003A1 (no) |
TW (1) | TWI356711B (no) |
WO (1) | WO2005004836A2 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60028754T2 (de) | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
EP2851075B1 (en) | 2012-05-14 | 2021-12-01 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
CA2124568C (en) * | 1992-10-09 | 2003-11-11 | Yoshiaki Yano | Method for producing microgranulated particle |
TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6514530B2 (en) * | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
AU3705799A (en) * | 1998-04-09 | 1999-11-01 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
JP2002532406A (ja) * | 1998-12-17 | 2002-10-02 | アルザ・コーポレーション | 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換 |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
EP1247456A3 (en) * | 2001-02-28 | 2003-12-10 | Pfizer Products Inc. | Palatable pharmaceutical compositions for companion animals |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
-
2004
- 2004-07-05 JP JP2006519808A patent/JP4608488B2/ja not_active Expired - Lifetime
- 2004-07-05 MX MXPA06000363A patent/MXPA06000363A/es active IP Right Grant
- 2004-07-05 RS YUP-2006/0009A patent/RS20060009A/sr unknown
- 2004-07-05 BR BRPI0412523-1A patent/BRPI0412523A/pt not_active IP Right Cessation
- 2004-07-05 KR KR1020067000732A patent/KR100767271B1/ko active IP Right Grant
- 2004-07-05 NZ NZ544585A patent/NZ544585A/en not_active IP Right Cessation
- 2004-07-05 AU AU2004255436A patent/AU2004255436B2/en not_active Ceased
- 2004-07-05 CA CA2531486A patent/CA2531486C/en not_active Expired - Lifetime
- 2004-07-05 EA EA200600156A patent/EA015349B1/ru not_active IP Right Cessation
- 2004-07-05 KR KR1020077016817A patent/KR20070087194A/ko not_active Application Discontinuation
- 2004-07-05 WO PCT/EP2004/007309 patent/WO2005004836A2/en active IP Right Grant
- 2004-07-05 EP EP04763093.4A patent/EP1646369B1/en not_active Expired - Lifetime
- 2004-07-07 TW TW093120382A patent/TWI356711B/zh not_active IP Right Cessation
- 2004-07-07 PE PE2004000651A patent/PE20050247A1/es not_active Application Discontinuation
- 2004-07-07 PA PA20048606001A patent/PA8606001A1/es unknown
- 2004-07-08 US US10/886,765 patent/US20050009811A1/en not_active Abandoned
- 2004-07-09 MY MYPI20042754A patent/MY140413A/en unknown
-
2005
- 2005-12-29 IL IL172890A patent/IL172890A/en not_active IP Right Cessation
-
2006
- 2006-01-05 CR CR8172A patent/CR8172A/es unknown
- 2006-01-06 TN TNP2006000003A patent/TNSN06003A1/en unknown
- 2006-01-06 MA MA28709A patent/MA27904A1/fr unknown
- 2006-01-06 CO CO06001295A patent/CO5640069A2/es not_active Application Discontinuation
- 2006-01-09 EC EC2006006274A patent/ECSP066274A/es unknown
- 2006-01-20 NO NO20060313A patent/NO20060313L/no not_active Application Discontinuation
- 2006-09-25 HK HK06110649.8A patent/HK1089959A1/xx not_active IP Right Cessation
-
2008
- 2008-10-31 US US12/262,607 patent/US20090054481A1/en not_active Abandoned
-
2010
- 2010-08-13 JP JP2010181350A patent/JP2010280707A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
RS77904A (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
EP1741712A3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol | |
YU58103A (sh) | Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona | |
TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
RS52904A (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
NO20060313L (no) | Saquinavirmesylat oral doseringsform | |
NO20061702L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist | |
NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
GR1003658B (el) | Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου | |
ATE390128T1 (de) | Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit | |
HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
UY28457A1 (es) | Nueva composición | |
TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
ATE389402T1 (de) | Sedierende nicht-benzodiazepin-formulierungen | |
SE0301371D0 (sv) | New Compounds | |
CO6341613A2 (es) | Compuestos de indanilo | |
AR041998A1 (es) | Formulaciones analgesicas orales de oxicodona de liberacion sostenida para administracion una vez al dia | |
TH79600B (th) | รูปแบบยาของแข็งที่ให้ทางปากที่มีขนาดของเอสตราไดออลต่ำ | |
TH79600A (th) | รูปแบบยาของแข็งที่ให้ทางปากที่มีขนาดของเอสตราไดออลต่ำ | |
MY145885A (en) | Controlled release formulations for oral administration | |
WO2005115092A3 (en) | Micronized oral pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |